Details for Patent: 8,216,604

Which drugs does patent 8,216,604 protect, and when does it expire?

Patent 8,216,604 protects LAZANDA and is included in one NDA.

This patent has thirty-five patent family members in twenty-four countries.

Summary for Patent: 8,216,604

Title:	Method of managing or treating pain
Abstract:	A composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (C.sub.max) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.
Inventor(s):	Watts; Peter James (Nottingham, GB), Castile; Jonathan David (Nottingham, GB), Lafferty; William Columbus Ian (Leicestershire, GB), Smith; Alan (Nottingham, GB)
Assignee:	Archimedes Development Limited (Nottingham, GB)
Application Number:	12/047,388
Patent Claim Types: see list of patent claims	Use; Composition; Formulation;

Drugs Protected by US Patent 8,216,604

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-001	Jun 30, 2011		DISCN	Yes	No						MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER
Btcp Pharma	LAZANDA	fentanyl citrate	SPRAY, METERED;NASAL	022569-002	Jun 30, 2011		DISCN	Yes	No						MANAGEMENT OF BREAKTHROUGH PAIN IN PATIENTS WITH CANCER

Foreign Priority and PCT Information for Patent: 8,216,604

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
United Kingdom	0300531.1	Jan 10, 2003

International Family Members for US Patent 8,216,604

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2004204381
Brazil	PI0406674
Canada	2511974
China	100423709
China	1723012
Cyprus	1115056